H3k79me1

Antibodies were purchased from the following companies: anti-H3K27me1, H3K27me3, H3K79me1, H3K79me2, histone H3, SETD2, and tubulin from Abcam; anti-hnRNP A2/B1 from Acris; anti-SRPK1 and SRPK2 from BD Biosciences; anti-AKT, H3K27me2, PP1, phospho-PP1 at Thr320, phospho-AKT at Ser473, and cleaved-CASPASE-3 from Cell Signaling Technology; anti-H3K4me1, H3K4me2, H3K4me3, and H3K36me3 from Millipore; anti-pro CASPASE-3 from GeneTex; anti-hnRNP C1/C2, BAX, BCL-2, and PARP from Santa Cruz Biotechnology; anti-hnRNP A1, SRSF6, and TRA2B from Sigma; and anti-SRSF1 and SRSF3 from Zymed.

Harvested cells were incubated in RIPA buffer (50 mM Tris–HCl [pH 8.0], 150 mM NaCl, 0.1% SDS, 0.5% SDC, 1% NP-40, 1× PIC and 1 mM EDTA [pH 8.0]) with gentle agitation at 4°C for 1 h. Cell lysates were clarified by centrifugation at 18 000 g for 15 min at 4°C. After SDS-PAGE, western blotting was performed using the following antibodies: SET/TAF-Iβ (sc-133138, 1:1000), MIB1 (sc-393551, 1:1000), p21 (sc-397, 1:1000), GFP (sc-9996, 1:1000), CBX8 (sc-374332, 1:1000) and β-actin (sc-47778, 1:1000) from Santa Cruz Biotechnology (Dallas, TX, USA); H2AK119ub (8240S, 1:5000), H3K4me3 (9751S, 1:5000) and H3K27me3 (9733S, 1:5000) from Cell Signaling Technology (Danvers, MA, USA); FLAG (F3165, 1:10 000) from Sigma-Aldrich; H3K36me1 (07-548, 1:5000), H3K36me3 (07-549, 1:5000), H3K4me2 (07-030, 1:5000), H3K9me2 (07-441, 1:5000), H3K9me3 (17–625, 1:5000), H2BK120ub (17-650, 1:5000), HA (05-904, 1:5000) and H3 (05-499, 1:5000) from Merck (Rahway, NJ, USA); RAD51 (GTX70230, 1:2500) from GeneTex (Irvine, CA, USA); H3K79me1 (ab2886, 1:5000), H3K79me2 (ab3594, 1:5000), H3K79me3 (ab2621, 1:5000) and H3K36me2 (ab9049, 1:5000) from Abcam (Cambridge, UK). β-actin (ACTIN) and histone H3 were used as loading controls.